Pharmaceutical companies are betting on a lesser-known form of cholesterol, Lp(a), to develop potentially blockbuster heart drugs. Historically, the focus has primarily been on LDL cholesterol and its role in cardiovascular disease. However, new research highlights that Lp(a) poses significant risks for heart attacks, with individuals having elevated levels facing more than double the risk compared to those without.
The decisive moment came as Novartis, Amgen, and Eli Lilly entered late-stage trials aimed at determining whether drugs that lower Lp(a) can effectively protect against heart attacks. The promising results from earlier studies indicate that these experimental drugs can reduce Lp(a) levels by over 80%, raising hopes for new treatment options in cardiology.
Currently, an estimated one in five people worldwide has elevated Lp(a). Despite this prevalence, less than 1% of adults in the U.S. were tested for it in 2024. This lack of cholesterol testing may hinder early intervention and treatment strategies that could save lives.
Experts like Dr. Steve Nissen emphasize the importance of keeping an open mind about cholesterol management strategies. He notes that previous beliefs about raising HDL cholesterol did not yield expected benefits, making the current focus on Lp(a) a potentially transformative approach. Jay Bradner adds that the clarity from population genetics supports this shift towards targeting Lp(a).
As companies like Novartis prepare for crucial trials—such as their upcoming study on pelacarsen—the industry watches closely. These trials will provide essential data on whether lowering Lp(a) can lead to fewer heart attacks and better outcomes for patients.
However, uncertainties remain regarding the exact levels of Lp(a) that need to be lowered to prevent heart attacks effectively. Additionally, delays in trial timelines due to slower-than-expected occurrences of heart attacks could impact when results will be available.
The potential rewards are significant; analysts project annual sales from these new therapies could reach $5.6 billion by 2032 if they prove successful. As pharmaceutical giants push forward with their research and development efforts, the stakes have never been higher.
This renewed focus on Lp(a) represents a pivotal moment in cardiology. It may redefine how we understand cholesterol’s role in cardiovascular health and reshape treatment protocols for millions at risk.
